Technology & Software Global On demand · 24-48h

Global Biomanufacturing in Bio-based Materials Market Strategic Research Report

Global Biomanufacturing in Bio-based Materials Market Strate…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biomanufacturing in Bio-based Materials Market
$5.47B2025
8.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Polysaccharide Polymers, Protein Polymers, Polyester Polymers, Others

By Application: Food & Beverage, Daily Chemicals, Medical, Packaging, Textiles, Automotive Industry, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Braskem, NatureWorks, Tate & Lyle, Fufeng Group, Meihua Group, Bloomage Biotech, Anhui BBCA Group, Lushang Freda, Total Corbion, Zhejiang Hisun Biomaterials, Pharmacosmos A/S, Danimer Scientific, Kingfa Sci.&Tech, Kewpie Corporation, Vedan Biotechnology, Giant Biogene, Contipro Inc., Shandong Topscience Biotech, Blue Ridge Tunhe, JNC Corporation, NAGASE, CJ Bio, Bluepha, Givaudan, RWDC Industries, Toyobo, PTT MCC Biochem, TianAn Biologic Materials Co, Kaneka, Jiangsu JLand Biotech, Jiangsu Chuangjian Medical Technology, Cathay Biotech Inc., Zhejiang Shengda Bio-Pharm, DANCHENG CAIXIN SUGAR INDUSTRY, CanSinoBIO, AMSilk GmbH, Shandong AWA Biopharm, Shandong Mimei Biotechnology, Juyou Bio-Technology, Shanghai Techwell Biopharmacieutical, Jinpu Nuoan Biotechnology, Jinyang Pharmaceutical, Ningxia Eppen Biotech, Kuraray, Shanxi Jinbo Bio-pharmaceutical, Wuhu Interferon, Evonik, TS-Biotech, Nanjing XuanKai Biotechnology, HTL Biotechnology, DSM, Hainan Guangyu Bio-technology, Kelun-Kazpharm, Highsun, Polybion, Spiber Inc., Chambroad Holding, Biozymes, Chihon Biotechnology, Namei Biotech, Xi'an Wanlong Pharmaceutical, Nacol Biotech, Mitsuboshi Kogyo Co., LG Chem, Leaf Bio, LINK SPIDER Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 100 pages
Market size 2025
$5.47B
Billion USD
Forecast CAGR
8.8%
2025-2032
Forecast 2032
$9.9B
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Biomanufacturing in Bio-based Materials market size is predicted to grow from US$ 5,466 million in 2025 to US$ 10,047 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

In the context of biomanufacturing, bio-based materials can be broadly categorized into three series: The first series consists of materials based on "bio-based monomers + chemical polymerization/modification," such as polylactic acid (PLA), some PBS chains, bio-based polyethylene (Bio-PE), and bio-based polyamide (Bio-PA). The industrialization logic for this type of material is closer to traditional chemical engineering: emphasizing large-scale production, engineering, and processing adaptability, with applications primarily in packaging, textiles, non-critical automotive components, and engineering plastics. The second series comprises polymeric materials that are "direct products of fermentation/biosynthesis," including PHA, xanthan gum, gellan gum, pullulan, bacterial cellulose, polylysine, and polyglutamic acid. These often enter the food, daily chemical, and some industrial processes as functional or formulated materials, demonstrating outstanding performance in film formation, rheological regulation, gelation, and biocompatibility. The third category is "recombinant protein materials," such as recombinant collagen and recombinant silk protein, elastin, fibronectin, mussel adhesive protein, etc., which are mainly aimed at medical and high-end consumer daily chemicals, emphasizing safety, consistency and evidence chain. Their industrialization path is closer to the logic of biopharmaceuticals and medical devices.

Governments worldwide, driven by environmental protection and circular economy goals, have enacted regulations and policies to forcefully promote the application of bio-based materials, creating a powerful external driving force. Typical examples include global plastic bans: the EU's SUP directive prohibits many single-use plastics, directly forcing a surge in the market for alternative materials such as PLA and PBAT; China and India have successively issued plastic bans, eliminating traditional plastic products across the board, forcing companies to seek biodegradable materials to meet production and packaging needs. Furthermore, carbon neutrality policies encourage low-carbon materials: the EU's proposed taxation of high-carbon products and the US's clean energy subsidies have increased or restricted the cost of petrochemical plastics, giving bio-based materials an early advantage due to their carbon reduction benefits. Government procurement also provides opportunities: the US BioPreferred program prioritizes the purchase of bio-based products by federal agencies, and some European countries require public projects to use environmentally friendly materials, providing the industry with an early and stable market. Future regulations are expected to become even stricter: for example, the proposed microplastics ban may exempt biodegradable polymers, guiding the industry to develop alternative technologies. In summary, strong policy support is driving the industry forward from both top-level design and actual enforcement, expanding market demand (such as the significant increase in demand for biodegradable bags in various markets) and providing guidance and impetus for R&D (companies are vying to develop new materials that meet regulatory requirements). It can be said that policy has become one of the most important single driving forces for bio-based materials today.

This report presents a comprehensive overview of the global Biomanufacturing in Bio-based Materials market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Polysaccharide Polymers
  • Protein Polymers
  • Polyester Polymers
  • Others

Segment by Technology

  • Biochemical Combination
  • Bio-fermentation
  • Others

Segment by Application

  • Food & Beverage
  • Daily Chemicals
  • Medical
  • Packaging
  • Textiles
  • Automotive Industry
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biomanufacturing in Bio-based Materials market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Food & Beverage, Daily Chemicals, Medical evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Biomanufacturing in Bio-based Materials Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$5.47B
2025
Forecast
$9.9B
2032
CAGR
8.8%
2025–2032
リージョン
5
global
Key companies
BraskemNatureWorksTate & LyleFufeng GroupMeihua GroupBloomage BiotechAnhui BBCA GroupLushang Freda
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Polysaccharide PolymersProtein PolymersPolyester PolymersOthers
By Application
Food & BeverageDaily ChemicalsMedicalPackagingTextilesAutomotive IndustryOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Polysaccharide Polymers
  • 3.1.3 Protein Polymers
  • 3.1.4 Polyester Polymers
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Food & Beverage
  • 4.1.3 Daily Chemicals
  • 4.1.4 Medical
  • 4.1.5 Packaging
  • 4.1.6 Textiles
  • 4.1.7 Automotive Industry
  • 4.1.8 Other
  • 4.1.9 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Braskem
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 NatureWorks
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Tate & Lyle
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Fufeng Group
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Meihua Group
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Bloomage Biotech
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Anhui BBCA Group
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Lushang Freda
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Total Corbion
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Zhejiang Hisun Biomaterials
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Pharmacosmos A/S
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Danimer Scientific
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Kingfa Sci.&Tech
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Kewpie Corporation
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Vedan Biotechnology
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Giant Biogene
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Contipro Inc.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Shandong Topscience Biotech
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Blue Ridge Tunhe
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 JNC Corporation
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 NAGASE
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 CJ Bio
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Bluepha
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Givaudan
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 RWDC Industries
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Toyobo
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 PTT MCC Biochem
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 TianAn Biologic Materials Co
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 Kaneka
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 Jiangsu JLand Biotech
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
  • 8.31 Jiangsu Chuangjian Medical Technology
  • 8.31.1 Company Overview
  • 8.31.2 Key Products & Segments
  • 8.31.3 Financial Performance (2023–2025)
  • 8.31.4 Business Strategy
  • 8.31.5 SWOT Analysis
  • 8.31.6 Strategic Implications (2026–2032)
  • 8.32 Cathay Biotech Inc.
  • 8.32.1 Company Overview
  • 8.32.2 Key Products & Segments
  • 8.32.3 Financial Performance (2023–2025)
  • 8.32.4 Business Strategy
  • 8.32.5 SWOT Analysis
  • 8.32.6 Strategic Implications (2026–2032)
  • 8.33 Zhejiang Shengda Bio-Pharm
  • 8.33.1 Company Overview
  • 8.33.2 Key Products & Segments
  • 8.33.3 Financial Performance (2023–2025)
  • 8.33.4 Business Strategy
  • 8.33.5 SWOT Analysis
  • 8.33.6 Strategic Implications (2026–2032)
  • 8.34 DANCHENG CAIXIN SUGAR INDUSTRY
  • 8.34.1 Company Overview
  • 8.34.2 Key Products & Segments
  • 8.34.3 Financial Performance (2023–2025)
  • 8.34.4 Business Strategy
  • 8.34.5 SWOT Analysis
  • 8.34.6 Strategic Implications (2026–2032)
  • 8.35 CanSinoBIO
  • 8.35.1 Company Overview
  • 8.35.2 Key Products & Segments
  • 8.35.3 Financial Performance (2023–2025)
  • 8.35.4 Business Strategy
  • 8.35.5 SWOT Analysis
  • 8.35.6 Strategic Implications (2026–2032)
  • 8.36 AMSilk GmbH
  • 8.36.1 Company Overview
  • 8.36.2 Key Products & Segments
  • 8.36.3 Financial Performance (2023–2025)
  • 8.36.4 Business Strategy
  • 8.36.5 SWOT Analysis
  • 8.36.6 Strategic Implications (2026–2032)
  • 8.37 Shandong AWA Biopharm
  • 8.37.1 Company Overview
  • 8.37.2 Key Products & Segments
  • 8.37.3 Financial Performance (2023–2025)
  • 8.37.4 Business Strategy
  • 8.37.5 SWOT Analysis
  • 8.37.6 Strategic Implications (2026–2032)
  • 8.38 Shandong Mimei Biotechnology
  • 8.38.1 Company Overview
  • 8.38.2 Key Products & Segments
  • 8.38.3 Financial Performance (2023–2025)
  • 8.38.4 Business Strategy
  • 8.38.5 SWOT Analysis
  • 8.38.6 Strategic Implications (2026–2032)
  • 8.39 Juyou Bio-Technology
  • 8.39.1 Company Overview
  • 8.39.2 Key Products & Segments
  • 8.39.3 Financial Performance (2023–2025)
  • 8.39.4 Business Strategy
  • 8.39.5 SWOT Analysis
  • 8.39.6 Strategic Implications (2026–2032)
  • 8.40 Shanghai Techwell Biopharmacieutical
  • 8.40.1 Company Overview
  • 8.40.2 Key Products & Segments
  • 8.40.3 Financial Performance (2023–2025)
  • 8.40.4 Business Strategy
  • 8.40.5 SWOT Analysis
  • 8.40.6 Strategic Implications (2026–2032)
  • 8.41 Jinpu Nuoan Biotechnology
  • 8.41.1 Company Overview
  • 8.41.2 Key Products & Segments
  • 8.41.3 Financial Performance (2023–2025)
  • 8.41.4 Business Strategy
  • 8.41.5 SWOT Analysis
  • 8.41.6 Strategic Implications (2026–2032)
  • 8.42 Jinyang Pharmaceutical
  • 8.42.1 Company Overview
  • 8.42.2 Key Products & Segments
  • 8.42.3 Financial Performance (2023–2025)
  • 8.42.4 Business Strategy
  • 8.42.5 SWOT Analysis
  • 8.42.6 Strategic Implications (2026–2032)
  • 8.43 Ningxia Eppen Biotech
  • 8.43.1 Company Overview
  • 8.43.2 Key Products & Segments
  • 8.43.3 Financial Performance (2023–2025)
  • 8.43.4 Business Strategy
  • 8.43.5 SWOT Analysis
  • 8.43.6 Strategic Implications (2026–2032)
  • 8.44 Kuraray
  • 8.44.1 Company Overview
  • 8.44.2 Key Products & Segments
  • 8.44.3 Financial Performance (2023–2025)
  • 8.44.4 Business Strategy
  • 8.44.5 SWOT Analysis
  • 8.44.6 Strategic Implications (2026–2032)
  • 8.45 Shanxi Jinbo Bio-pharmaceutical
  • 8.45.1 Company Overview
  • 8.45.2 Key Products & Segments
  • 8.45.3 Financial Performance (2023–2025)
  • 8.45.4 Business Strategy
  • 8.45.5 SWOT Analysis
  • 8.45.6 Strategic Implications (2026–2032)
  • 8.46 Wuhu Interferon
  • 8.46.1 Company Overview
  • 8.46.2 Key Products & Segments
  • 8.46.3 Financial Performance (2023–2025)
  • 8.46.4 Business Strategy
  • 8.46.5 SWOT Analysis
  • 8.46.6 Strategic Implications (2026–2032)
  • 8.47 Evonik
  • 8.47.1 Company Overview
  • 8.47.2 Key Products & Segments
  • 8.47.3 Financial Performance (2023–2025)
  • 8.47.4 Business Strategy
  • 8.47.5 SWOT Analysis
  • 8.47.6 Strategic Implications (2026–2032)
  • 8.48 TS-Biotech
  • 8.48.1 Company Overview
  • 8.48.2 Key Products & Segments
  • 8.48.3 Financial Performance (2023–2025)
  • 8.48.4 Business Strategy
  • 8.48.5 SWOT Analysis
  • 8.48.6 Strategic Implications (2026–2032)
  • 8.49 Nanjing XuanKai Biotechnology
  • 8.49.1 Company Overview
  • 8.49.2 Key Products & Segments
  • 8.49.3 Financial Performance (2023–2025)
  • 8.49.4 Business Strategy
  • 8.49.5 SWOT Analysis
  • 8.49.6 Strategic Implications (2026–2032)
  • 8.50 HTL Biotechnology
  • 8.50.1 Company Overview
  • 8.50.2 Key Products & Segments
  • 8.50.3 Financial Performance (2023–2025)
  • 8.50.4 Business Strategy
  • 8.50.5 SWOT Analysis
  • 8.50.6 Strategic Implications (2026–2032)
  • 8.51 DSM
  • 8.51.1 Company Overview
  • 8.51.2 Key Products & Segments
  • 8.51.3 Financial Performance (2023–2025)
  • 8.51.4 Business Strategy
  • 8.51.5 SWOT Analysis
  • 8.51.6 Strategic Implications (2026–2032)
  • 8.52 Hainan Guangyu Bio-technology
  • 8.52.1 Company Overview
  • 8.52.2 Key Products & Segments
  • 8.52.3 Financial Performance (2023–2025)
  • 8.52.4 Business Strategy
  • 8.52.5 SWOT Analysis
  • 8.52.6 Strategic Implications (2026–2032)
  • 8.53 Kelun-Kazpharm
  • 8.53.1 Company Overview
  • 8.53.2 Key Products & Segments
  • 8.53.3 Financial Performance (2023–2025)
  • 8.53.4 Business Strategy
  • 8.53.5 SWOT Analysis
  • 8.53.6 Strategic Implications (2026–2032)
  • 8.54 Highsun
  • 8.54.1 Company Overview
  • 8.54.2 Key Products & Segments
  • 8.54.3 Financial Performance (2023–2025)
  • 8.54.4 Business Strategy
  • 8.54.5 SWOT Analysis
  • 8.54.6 Strategic Implications (2026–2032)
  • 8.55 Polybion
  • 8.55.1 Company Overview
  • 8.55.2 Key Products & Segments
  • 8.55.3 Financial Performance (2023–2025)
  • 8.55.4 Business Strategy
  • 8.55.5 SWOT Analysis
  • 8.55.6 Strategic Implications (2026–2032)
  • 8.56 Spiber Inc.
  • 8.56.1 Company Overview
  • 8.56.2 Key Products & Segments
  • 8.56.3 Financial Performance (2023–2025)
  • 8.56.4 Business Strategy
  • 8.56.5 SWOT Analysis
  • 8.56.6 Strategic Implications (2026–2032)
  • 8.57 Chambroad Holding
  • 8.57.1 Company Overview
  • 8.57.2 Key Products & Segments
  • 8.57.3 Financial Performance (2023–2025)
  • 8.57.4 Business Strategy
  • 8.57.5 SWOT Analysis
  • 8.57.6 Strategic Implications (2026–2032)
  • 8.58 Biozymes
  • 8.58.1 Company Overview
  • 8.58.2 Key Products & Segments
  • 8.58.3 Financial Performance (2023–2025)
  • 8.58.4 Business Strategy
  • 8.58.5 SWOT Analysis
  • 8.58.6 Strategic Implications (2026–2032)
  • 8.59 Chihon Biotechnology
  • 8.59.1 Company Overview
  • 8.59.2 Key Products & Segments
  • 8.59.3 Financial Performance (2023–2025)
  • 8.59.4 Business Strategy
  • 8.59.5 SWOT Analysis
  • 8.59.6 Strategic Implications (2026–2032)
  • 8.60 Namei Biotech
  • 8.60.1 Company Overview
  • 8.60.2 Key Products & Segments
  • 8.60.3 Financial Performance (2023–2025)
  • 8.60.4 Business Strategy
  • 8.60.5 SWOT Analysis
  • 8.60.6 Strategic Implications (2026–2032)
  • 8.61 Xi'an Wanlong Pharmaceutical
  • 8.61.1 Company Overview
  • 8.61.2 Key Products & Segments
  • 8.61.3 Financial Performance (2023–2025)
  • 8.61.4 Business Strategy
  • 8.61.5 SWOT Analysis
  • 8.61.6 Strategic Implications (2026–2032)
  • 8.62 Nacol Biotech
  • 8.62.1 Company Overview
  • 8.62.2 Key Products & Segments
  • 8.62.3 Financial Performance (2023–2025)
  • 8.62.4 Business Strategy
  • 8.62.5 SWOT Analysis
  • 8.62.6 Strategic Implications (2026–2032)
  • 8.63 Mitsuboshi Kogyo Co.
  • 8.63.1 Company Overview
  • 8.63.2 Key Products & Segments
  • 8.63.3 Financial Performance (2023–2025)
  • 8.63.4 Business Strategy
  • 8.63.5 SWOT Analysis
  • 8.63.6 Strategic Implications (2026–2032)
  • 8.64 LG Chem
  • 8.64.1 Company Overview
  • 8.64.2 Key Products & Segments
  • 8.64.3 Financial Performance (2023–2025)
  • 8.64.4 Business Strategy
  • 8.64.5 SWOT Analysis
  • 8.64.6 Strategic Implications (2026–2032)
  • 8.65 Leaf Bio
  • 8.65.1 Company Overview
  • 8.65.2 Key Products & Segments
  • 8.65.3 Financial Performance (2023–2025)
  • 8.65.4 Business Strategy
  • 8.65.5 SWOT Analysis
  • 8.65.6 Strategic Implications (2026–2032)
  • 8.66 LINK SPIDER Co.,Ltd.
  • 8.66.1 Company Overview
  • 8.66.2 Key Products & Segments
  • 8.66.3 Financial Performance (2023–2025)
  • 8.66.4 Business Strategy
  • 8.66.5 SWOT Analysis
  • 8.66.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Biomanufacturing in Bio-based Materials market?
The global Biomanufacturing in Bio-based Materials market is estimated at US$ 5.47 billion in 2025 (base year) and is projected to reach US$ 10.05 billion by 2032.
What is the forecast CAGR for the Biomanufacturing in Bio-based Materials market?
The market is expected to grow at a CAGR of 8.8% from 2026 to 2032, expanding from US$ 5.47 billion in 2025 to US$ 10.05 billion in 2032, roughly 1.8 times its base-year value.
What is Biomanufacturing in Bio-based Materials?
In the context of biomanufacturing, bio-based materials can be broadly categorized into three series: The first series consists of materials based on "bio-based monomers + chemical polymerization/modification," such as polylactic acid (PLA), some PBS chains, bio-based polyethylene (Bio-PE), and bio-based polyamide (Bio-PA). The second series comprises polymeric materials that are "direct products of fermentation/biosynthesis," including PHA, xanthan gum, gellan gum, pullulan, bacterial cellulose, polylysine, and polyglutamic acid.
What are the main segments of the Biomanufacturing in Bio-based Materials market by type?
By type, the market is segmented into Polysaccharide Polymers, Protein Polymers, Polyester Polymers and Others.
Which applications drive demand in the Biomanufacturing in Bio-based Materials market?
Key applications covered include Food & Beverage, Daily Chemicals, Medical, Packaging, Textiles, Automotive Industry and Other.
Who are the key players in the Biomanufacturing in Bio-based Materials market?
Key players profiled include Braskem, NatureWorks, Tate & Lyle, Fufeng Group, Meihua Group, Bloomage Biotech, Anhui BBCA Group and Lushang Freda, among 66 companies covered in total.
Which regions and countries are covered for Biomanufacturing in Bio-based Materials?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Biomanufacturing in Bio-based Materials market?
Governments worldwide, driven by environmental protection and circular economy goals, have enacted regulations and policies to forcefully promote the application of bio-based materials, creating a powerful external driving force.
Who should buy the Biomanufacturing in Bio-based Materials market report?
The report is intended for manufacturers and solution providers, distributors and end users in Food & Beverage, Daily Chemicals and Medical, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Biomanufacturing in Bio-based Materials market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.